Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZD-1839 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| ZD1839 (IRESSA™) | DRUG | - |
| Docetaxel | DRUG | - |
| Cisplatin | DRUG | - |
| ZD-1839 | DRUG | - |
Inclusion Criteria: 1. Male or female, aged 18 and 70 years, inclusive 2. Histologically- or cytologically-confirmed recurrent and/or metastatic SCCHN 3. Primary tumour site of oral cavity, oropharynx, hypopharynx or larynx 4. At least one uni-dimensionally measurable lesion according to the RECIST...
Top 20 of 58 competitors
ZD-1839 is an investigational small molecule being studied in oncology for the treatment of mesothelioma, prostate cancer, head and neck cancer, and carcinoma. It is being developed by AstraZeneca PLC (AZN) and has completed clinical trials in these indications.
ZD-1839 is a small molecule that targets the epidermal growth factor receptor (EGFR), a protein involved in cell growth and division. By inhibiting EGFR, ZD-1839 aims to slow or stop the growth of cancer cells that rely on this signaling pathway.
ZD-1839 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. AstraZeneca is conducting clinical trials to evaluate the safety and effectiveness of ZD-1839 in various cancer types.
ZD-1839 is in Phase 2 clinical development. It has completed two Phase 2 trials and one Phase 1 trial, with no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities for any indication.
ZD-1839 has completed four clinical trials, including NCT00185835 (Phase 1, head and neck cancer), NCT00242762 (Phase 2, head and neck cancer), NCT00242918 (Phase 2, prostate cancer), and NCT00787410 (Phase 2, mesothelioma). All trials are completed with a total enrollment of 46 patients.
ZD-1839 is also known as IRESSA, as indicated in the clinical trial titles. IRESSA is the brand name used in studies such as NCT00242762 and NCT00787410. Both names refer to the same investigational drug being developed by AstraZeneca.